| dc.description.abstract | Introduction Despite the novel technical and medical improvement in performing of percutaneous coronary intervention (PCI), some myocardial complications occur during this procedure. Thus, periprocedural myocardial injury (PMI) following PCI has received serious attention due to its notable relation to mortality and morbidity. Therefore, cardioprotection during PCI is still a worldwide need. Aim Concerning the potential clinical benefits of CoQ10, this trial was performed to investigate the CoQ10 pretreatment benefits in reduction of PMI in patients undergoing elective PCI.Methods A randomized controlled trial of 100 patients undergoing elective PCI was designed. The intervention group (n=50) received 300 mg CoQ10 in a single dose and the standard treatment 12 hours before PCI. But the control group (n=50) had the standard treatment only. To evaluate the myocardial injury during PCI, the levels of CK-MB and troponine-I were measured at baseline, 8 h, and 24 h after PCI, and hs-CRP levels were measured at baseline and 24 h after PCI. Afterwards, all patients were assessed for the major adverse cardiac effects in a 1-month following up period.Results No significant changes in the CK-MB levels at 8 h (p=0.079) and 24 h (p=0.242) following PCI were found in intervention group when compared with the control group. In the same way, no significant changes in troponine-I at 8 h (p=0.062) and 24 h (p=0.826) after PCI were observed. The results of hs-CRP levels indicated significant changes at 24 h (p=0.031) after PCI.Conclusions Although the biomarkers changes were not significant in intervention group, there was a trend toward the potential benefits of CoQ10. On the other hand, the changes of hs-CRP were statistically significant, that can relatively support the potential cardioprotective effects of CoQ10 in the prevention of PMI following PCI. | |
